country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P12142

Copy Link Print Information

GLP‐1 receptor agonist D13

GLP-1 receptor agonist D13 is a long-acting GLP-1R agonist peptide conjugated with a C20 fatty acid chain. It activates GLP-1R-mediated cAMP signaling in HEK293 cells, with an EC₅₀ of 0.036 nM. GLP-1 receptor agonist D13 can be used in studies related to type 2 diabetes, diabetic nephropathy and obesity.

For research use only. We do not sell to patients.

Formula: C₁₈₇H₃₀₂N₄₈O₆₁
Molecular Weight:4198.68

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

GLP‐1 receptor agonist D13 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

GLP-1R

0.036 nM (EC₅₀)

In Vitro

The GLP-1 receptor agonist D13 (compound D13) (0.003-800 nM; 30 min; HEK293 cells stably expressing human GLP-1R) activates intracellular cAMP signaling, with an EC₅₀ of 0.036 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	T_1/2	C_max	T_max
Rat^[1]	0.05 mg/kg	s.c.	19.86 h	353.96 ng/mL	10.67 h

In Vivo

The GLP-1 receptor agonist D13 (compound D13) (10 nmol/kg; s.c.; single administration) reduces non-fasting blood glucose in male db/db mice starting at 0.5 h post-administration, with the effect lasting approximately 96 h and the lowest blood glucose level reaching 15.53 mmol/L^[1].
GLP-1 receptor agonist D13 (10 nmol/kg; s.c.; once daily; 28 days) persistently reduces non-fasting blood glucose in male db/db mice, with the effect lasting approximately 96 h after the final administration; GLP-1 receptor agonist D13 improves glucose tolerance, with an iPGTT AUC_{0-180 min} of 2725.75 mmol·L⁻¹·min^[1].
The GLP-1 receptor agonist D13 (10 nmol/kg; s.c.; once daily; 28 days) reduces blood urea nitrogen (BUN), serum creatinine (Scr) and urinary albumin levels, and increases urinary creatinine levels in male db/db mice.
The GLP-1 receptor agonist D13 (10 nmol/kg) reduces body weight by 19.25%; meanwhile, it decreases the liver index, fat index, and serum LDL-C^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6J db/db (male, diabetic nephropathy model); db/m (male, control)^[1]
Dosage:

10 nmol/kg
Administration:

s.c.; single dose; daily for 28 days
Result:

Produced sustained glucose lowering for approximately 96 h after the final administration.
Improved glucose tolerance with an iPGTT AUC0-180 min of 2725.75 mmol·L−1·min.
Reduced BUN, serum creatinine and urinary albumin and increased urinary creatinine.

Animal Model:

C57BL/6J (male, diet-induced obesity model)^[1]
Dosage:

10 nmol/kg
Administration:

s.c.; daily; 28 days
Result:

Induced a 19.25% reduction in body weight, comparable to the 21.54% reduction seen with Semaglutide.
Reduced 4-hour fasting blood glucose, liver index, fat index, and serum LDL-C levels.

Chemical Information

Molecular Weight 4198.68
Formula C₁₈₇H₃₀₂N₄₈O₆₁
SMILES

O=C(NC(C)(C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)C(N[C@@H](C)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CCCNC(N)=N)C(NCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC4=CNC=N4)N
Sequence

His-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Glu-Gln-Ala-Ala-Lys(AEEA-AEEA-γGlu-C20 diacid)-Ala-Phe-Val-Glu-Arg-Leu-Lys-Arg-Gly-Arg-Gly
Sequence Shortening

H-{Aib}-EGTFTSDVSSYLEEQAA-Lys(AEEA-AEEA-γGlu-C20 diacid)-AFVERLKRGRG
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Wei T, et al. AI-Driven De Novo Design of Ultra Long-Acting GLP-1 Receptor Agonists. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2025 Oct;12(40):e07044. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote